This is a secondary-prevention result, not a general heart-health claim, and it belongs to the full obesity dose
Individual ingredient amounts in the proprietary blend aren't disclosed - that's a standard proprietary-blend format, not unique to this product
How GLP-1 Prescribing Standards Apply to Telehealth Platforms The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in June 2021 under a specific label that includes a Risk Evaluation and Mitigation Strategy (REMS) requirement for MTC and MEN2 screening 20
When compounded semaglutide contains the same active ingredient, it works through the same biological pathways to reduce appetite, regulate blood sugar, and promote weight loss
This luxurious blend, enriched with skin-strengthening lipids and a Vitamin F blend featuring Omega-rich chia seed oil, restores your skin's moisture barrier, enhancing elasticity, plumpness, and suppleness
doi: 10.3389/fendo.2023.1217165